NCT02636842View on ClinicalTrials.gov

A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Aripiprazole Lauroxil

Intramuscular (IM) injection, single dose

Trial Locations (6)

60169

Alkermes Investigational Site, Hoffman Estates

75243

Alkermes Investigative Site, Dallas

80530

Alkermes Investigational Site, Marlton

90703

Alkermes Investigational Site, Cerritos

91945

Alkermes Investigational Site, Lemon Grove

94612

Alkermes Investigational Site, Oakland

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY

NCT02636842 - A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder | Biotech Hunter | Biotech Hunter